媒合條件:
United Immunity
- United Immunity challenges conquest of intractable solid cancer where conventional therapies are not effective for, by developing novel combination immunotherapies utilizing its potent anti-tumor T cell activating nano-immunotherapy “T-ignite”, The same technology is being used for the development of a next generation delta strain-reactive SARS-CoV-2 vaccine.
- United Immunity is a clinical stage company with three pipelines. A small P1 study (physician-initiative study) of UI-201 in combination with TCR-T was completed in 3 synovial sarcoma patients in Japan. The safety and effectiveness of UI-201 is at least partly proven. They will be proven in larger scale clinical studies. UI-101 is prepared for a series of pre-clinical studies. UI-101 is meant to be used in combination with anti-PD-1/PD-L1 antibody. In addition, this drug can be also expected to be used in combination with other type of immune-oncology drugs. Delta strain SARS-CoV-2 nanoparticle vaccine will go into FIH clinical study in 2022.
- United Immunity is seeking alliance partners for UI-101, 201 and SARS-CoV-2 nanoparticle vaccines for out-licensing opportunity or co-development. The platform technology of T-Ignite can be applied to not only limited to oncology/infection, but also to other therapeutic areas where macrophage or dendritic cells are contributed. i.e. NASH, osteoporosis, fibrosis, and others. United Immunity is also seeking alliance partners for collaboration research to produce clinical/pre-clinical development candidates.
Japan
國際協會
© Institute for Biotechnology and Medicine Industry & Research Center for Biotechnology and Medicine Policy
聯絡我們
Loading...